These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15288330)

  • 21. Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women.
    Dunkin J; Rasgon N; Wagner-Steh K; David S; Altshuler L; Rapkin A
    Psychoneuroendocrinology; 2005 Apr; 30(3):284-96. PubMed ID: 15511602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of cognitive rehabilitation on cognitive competence in patients with Alzheimer's disease.
    Oresnik M
    Psychiatr Danub; 2008 Jun; 20(2):174-8. PubMed ID: 18587287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The existence of cognitive plateaus in Alzheimer's disease.
    Bozoki AC; An H; Bozoki ES; Little RJ
    Alzheimers Dement; 2009 Nov; 5(6):470-8. PubMed ID: 19896586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease.
    Mok WY; Chu LW; Chung CP; Chan NY; Hui SL
    Int J Geriatr Psychiatry; 2004 Nov; 19(11):1040-6. PubMed ID: 15481076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Instability of cognitive asymmetry in Alzheimer's disease.
    Xeno Rasmusson D; Brandt J
    J Clin Exp Neuropsychol; 1995 May; 17(3):449-58. PubMed ID: 7650106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of the Algase Wandering Scale in an outpatient Alzheimer's disease sample.
    Marcus JF; Cellar JS; Ansari FP; Bliwise DL
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):801-5. PubMed ID: 17193340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease.
    Stavitsky K; Brickman AM; Scarmeas N; Torgan RL; Tang MX; Albert M; Brandt J; Blacker D; Stern Y
    Arch Neurol; 2006 Oct; 63(10):1450-6. PubMed ID: 17030662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing motor and cognitive regulation in AD, MCI, and controls using the Behavioral Dyscontrol Scale.
    Belanger HG; Wilder-Willis K; Malloy P; Salloway S; Hamman RF; Grigsby J
    Arch Clin Neuropsychol; 2005 Mar; 20(2):183-9. PubMed ID: 15708728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depressive symptoms in Alzheimer's disease: natural course and temporal relation to function and cognitive status.
    Holtzer R; Scarmeas N; Wegesin DJ; Albert M; Brandt J; Dubois B; Hadjigeorgiou GM; Stern Y
    J Am Geriatr Soc; 2005 Dec; 53(12):2083-9. PubMed ID: 16398891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
    Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a composite score as an easy-to-use instrument for clinical monitoring of dementia progression: the Composite Cognitive and Activities of Daily Living Functioning Score.
    Melis RJ; Angleman SB; Fratiglioni L
    J Am Geriatr Soc; 2011 Jun; 59(6):1154-5. PubMed ID: 21668928
    [No Abstract]   [Full Text] [Related]  

  • 34. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
    Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
    Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease.
    Spalletta G; Baldinetti F; Buccione I; Fadda L; Perri R; Scalmana S; Serra L; Caltagirone C
    J Neurol; 2004 Jun; 251(6):688-95. PubMed ID: 15311344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of education on the pattern of cognitive deterioration in AD patients: the cognitive reserve hypothesis.
    Le Carret N; Auriacombe S; Letenneur L; Bergua V; Dartigues JF; Fabrigoule C
    Brain Cogn; 2005 Mar; 57(2):120-6. PubMed ID: 15708201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Screening of cognitive functions and the prediction of incident dementia by means of the SIDAM].
    Bickel H; Mösch E; Förstl H
    Psychiatr Prax; 2007 Apr; 34(3):139-44. PubMed ID: 17443456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.
    Ito T; Meguro K; Akanuma K; Meguro M; Lee E; Kasuya M; Ishii H; Mori E
    J Clin Neurosci; 2007 Sep; 14(9):850-5. PubMed ID: 17587584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.